Obamacare and You: If You Have Medicare…
This short explainer highlights some of the key information for people with Medicare about how Affordable Care Act, also known as Obamacare, may affect them.
View the Latest: Medicare Part D
Filter
-
-
Medicare Advantage 2013 Spotlight: Enrollment Market Update
Issue BriefThis Data Spotlight provides an overview of Medicare Advantage enrollment patterns in March 2013, and examines variations by plan type, state, and firm. It also analyzes trends in premiums paid by beneficiaries enrolled in Medicare Advantage plans, including variations by plan type, and describes the out-of-pocket limits and prescription drug coverage in the Part D “donut hole” provided by the plans in 2013.
-
A Status Report on Prescription Drug Policies and Proposals at the Start of the Biden Administration
Issue BriefThis brief provides a status update on prescription drug final rules advanced by the Trump Administration in its final months related to Medicare, importation, and 340B pricing for insulin and epinephrine, and an overview of key drug pricing proposals related to Medicare and prescription drug prices generally that were voted on but not enacted in the previous Congress that may return to the forefront of health policy discussions in the coming years.
-
Key Facts About Medicare Part D Enrollment, Premiums, and Cost Sharing in 2021
Issue BriefThe Medicare Part D program provides an outpatient prescription drug benefit to older adults and people with long-term disabilities in Medicare who enroll in private plans, including stand-alone drug plans and Medicare Advantage drug plans. This analysis provides the latest data about Part D enrollment, premiums, and cost sharing in 2021 and trends over time.
-
Millions of Medicare Part D Enrollees Have Had Out-of-Pocket Drug Costs High Enough to Exceed the Catastrophic Threshold Over Time
News ReleaseNearly 3 million Medicare Part D enrollees had out-of-pocket drug spending above the catastrophic threshold in a recent five-year period, finds a new KFF analysis that takes a comprehensive look at how many people on Medicare have drug expenses high enough to push them above that limit.
-
How Would Drug Price Negotiation Affect Medicare Part D Premiums?
Issue BriefProposals to allow the federal government to negotiate prescription drug prices, such as H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, aim to lower out-of-pocket drug costs for Medicare beneficiaries and private plan enrollees and achieve savings for Medicare. This data note estimates average premium savings attributable to the negotiations provision of H.R. 3 on a per capita basis for Part D enrollees who pay premiums in dollar amounts and as a share of the base beneficiary premium, based on aggregate premium reductions and baseline premiums projected by Medicare’s actuaries through 2029.
-
Who Didn’t Get a Second Shingrix Shot? Implications for Multidose COVID-19 Vaccines
Issue BriefAs the U.S. prepares for nationwide distribution of vaccines to combat COVID-19, some are asking whether people who get the first of two doses will return to complete the series. This analysis draws on Medicare Part D prescription drug claims data for the herpes zoster vaccine Shingrix, which also requires two doses, to shed light on this potential challenge of the leading COVID-19 vaccine candidates.
-
A Medicare Prescription Drug Benefit: Implications for Medicaid and Low-Income People
ReportThe Senate and House of Representatives each approved legislation in June of 2003 that would establish outpatient prescription drug coverage for Medicare beneficiaries as part of Medicare program reform.
-
Prescription Drug Coverage for Medicare Beneficiaries: A Side-by-Side Comparison of S. 1 and H.R. 1 and the Conference Agreement H.R. 1
ReportThis document, prepared by Health Policy Alternatives, Inc., provides a detailed side-by-side comparison of the prescription drug provisions of the Conference Agreement (H.R. 1) passed by the House and Senate in November 2003 and the House (H.R. 1) and Senate (S. 1) Medicare proposals passed in June 2003. Report (.
-
The Kaiser Family Foundation/Harvard School of Public Health Medicare Prescription Drug Survey – Chartpack
ReportThis chartpack is part of a survey by the Kaiser Family Foundation and Harvard School of Public Health that examines public opinion on the Medicare prescription drug debate.